Artelo OKd on Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor

 ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment

Phase 1 trial results expected in the first half of 2025

https://www.globenewswire.com/news-release/2024/07/15/2913045/0/en/Artelo-Biosciences-Receives-FDA-Clearance-of-its-IND-Application-for-ART26-12-a-Selective-Fatty-Acid-Binding-Protein-5-Inhibitor.html